Primer on Statistics for Interventional Cardiologists Giuseppe Sangiorgi, MD Pierfrancesco Agostoni, MD Giuseppe Biondi-Zoccai, MD.

Slides:



Advertisements
Similar presentations
Sibbing D, et al. J Am Coll Cardiol 2009;53:
Advertisements

When PCI in NSTEMI? Giuseppe Biondi Zoccai, MD Department of Medico-Surgical Sciences and Biotechnologies Sapienza University of Rome.
Introduction to Survival Analysis October 19, 2004 Brian F. Gage, MD, MSc with thanks to Bing Ho, MD, MPH Division of General Medical Sciences.
STENT THROMBOSIS: WHICH IMPACT IN REAL CLINICAL PRACTICE? Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino Ospedale S. Giovanni Battista.
بسم الله الرحمن الرحیم. Generally,survival analysis is a collection of statistical procedures for data analysis for which the outcome variable of.
Main Points to be Covered Cumulative incidence using life table method Difference between cumulative incidence based on proportion of persons at risk and.
Measures of disease frequency (I). MEASURES OF DISEASE FREQUENCY Absolute measures of disease frequency: –Incidence –Prevalence –Odds Measures of association:
Mann-Whitney and Wilcoxon Tests.
Survival Analysis A Brief Introduction Survival Function, Hazard Function In many medical studies, the primary endpoint is time until an event.
Analysis of Complex Survey Data
8/15/2015Slide 1 The only legitimate mathematical operation that we can use with a variable that we treat as categorical is to count the number of cases.
Survival analysis Brian Healy, PhD. Previous classes Regression Regression –Linear regression –Multiple regression –Logistic regression.
Overall agenda Part 1 and 2  Part 1: Basic statistical concepts and descriptive statistics summarizing and visualising data describing data -measures.
Primer on Statistics for Interventional Cardiologists Giuseppe Sangiorgi, MD Pierfrancesco Agostoni, MD Giuseppe Biondi-Zoccai, MD.
Advanced Statistics for Interventional Cardiologists.
Essentials of survival analysis How to practice evidence based oncology European School of Oncology July 2004 Antwerp, Belgium Dr. Iztok Hozo Professor.
HSRP 734: Advanced Statistical Methods July 10, 2008.
Dr Laura Bonnett Department of Biostatistics. UNDERSTANDING SURVIVAL ANALYSIS.
Copyright © 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins Chapter 17 Inferential Statistics.
1 Introduction to medical survival analysis John Pearson Biostatistics consultant University of Otago Canterbury 7 October 2008.
X Treatment population Control population 0 Examples: Drug vs. Placebo, Drugs vs. Surgery, New Tx vs. Standard Tx  Let X =  cholesterol level (mg/dL);
A Systematic Review On The Hazards Of Aspirin Discontinuation Among Patients With Or At Risk For Coronary Artery Disease Giuseppe Biondi Zoccai Hemodynamics.
Statistical analysis Prepared and gathered by Alireza Yousefy(Ph.D)
Tips and tricks for performing standard meta-regression analysis with SPSS Giuseppe Biondi Zoccai Division of Cardiology, Department of Internal Medicine,
INTRODUCTION TO SURVIVAL ANALYSIS
01/20151 EPI 5344: Survival Analysis in Epidemiology Survival curve comparison (non-regression methods) March 3, 2015 Dr. N. Birkett, School of Epidemiology,
Introduction to Survival Analysis Utah State University January 28, 2008 Bill Welbourn.
Primer on Statistics for Interventional Cardiologists Giuseppe Sangiorgi, MD Pierfrancesco Agostoni, MD Giuseppe Biondi-Zoccai, MD.
Primer on Statistics for Interventional Cardiologists Giuseppe Sangiorgi, MD Pierfrancesco Agostoni, MD Giuseppe Biondi-Zoccai, MD.
Primer on Statistics for Interventional Cardiologists Giuseppe Sangiorgi, MD Pierfrancesco Agostoni, MD Giuseppe Biondi-Zoccai, MD.
Giuseppe Biondi Zoccai Division of Cardiology University of Turin, Turin Critical aspects of trials on the new generation DES 31st.
Statistical Inference for more than two groups Peter T. Donnan Professor of Epidemiology and Biostatistics Statistics for Health Research.
Is personalized medicine a hoax? Giuseppe Biondi Zoccai, MD University of Modena and Reggio Emilia
Lecture 9: Analysis of intervention studies Randomized trial - categorical outcome Measures of risk: –incidence rate of an adverse event (death, etc) It.
Intravascular ultrasound does not provide any significant clinical benefit for percutaneous coronary intervention of bifurcation lesions Giuseppe Biondi.
TAXUS Landmark Analysis Impact of Long-Term Clopidogrel Usage on Death, Myocardial Infarction and Stent Thrombosis Gregg W. Stone, MD Stephen G. Ellis,
Upendra Kaul, MD for the TUXEDO INDIA Investigators Paclitaxel Eluting Versus Everolimus Eluting Stents in Patients with Diabetes Mellitus and Coronary.
Advanced Statistics for Interventional Cardiologists.
Giuseppe Biondi Zoccai University of Turin, Turin, Italy METCARDIO, Turin, Italy JOINT SYMPOSIUM WITH JACCT - Bologna, 25/9/2008.
Survival Analysis approach in evaluating the efficacy of ARV treatment in HIV patients at the Dr GM Hospital in Tshwane, GP of S. Africa Marcus Motshwane.
01/20151 EPI 5344: Survival Analysis in Epidemiology Actuarial and Kaplan-Meier methods February 24, 2015 Dr. N. Birkett, School of Epidemiology, Public.
Primer on Statistics for Interventional Cardiologists Giuseppe Sangiorgi, MD Pierfrancesco Agostoni, MD Giuseppe Biondi-Zoccai, MD.
Satistics 2621 Statistics 262: Intermediate Biostatistics Jonathan Taylor and Kristin Cobb April 20, 2004: Introduction to Survival Analysis.
Primer on Statistics for Interventional Cardiologists Giuseppe Sangiorgi, MD Pierfrancesco Agostoni, MD Giuseppe Biondi-Zoccai, MD.
Primer on Statistics for Interventional Cardiologists Giuseppe Sangiorgi, MD Pierfrancesco Agostoni, MD Giuseppe Biondi-Zoccai, MD.
Some survival basics Developments from the Kaplan-Meier method October
INTRODUCTION TO CLINICAL RESEARCH Survival Analysis – Getting Started Karen Bandeen-Roche, Ph.D. July 20, 2010.
Primer on Statistics for Interventional Cardiologists Giuseppe Sangiorgi, MD Pierfrancesco Agostoni, MD Giuseppe Biondi-Zoccai, MD.
Drug-eluting stent meta-analyses & Long-term follow-up of high-risk subsets: Reconciling the evidence DES e BMS: riflessioni e pensieri 23 febbraio 2007,
1 Superiority Of A Simple Stenting Strategy For Coronary Bifurcation Lesions In The Drug-Eluting Stent Era: Evidence From A Meta-Analysis Of 1141 Patients.
Topic 19: Survival Analysis T = Time until an event occurs. Events are, e.g., death, disease recurrence or relapse, infection, pregnancy.
1 Chapter 6 SAMPLE SIZE ISSUES Ref: Lachin, Controlled Clinical Trials 2:93-113, 1981.
Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.
Drug-Eluting Stents in Challenging Lesions: Randomized Trials and Registries.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Smoking Is Associated With Adverse Clinical Outcomes.
SURVIVAL ANALYSIS PRESENTED BY: DR SANJAYA KUMAR SAHOO PGT,AIIH&PH,KOLKATA.
Methods and Statistical analysis. A brief presentation. Markos Kashiouris, M.D.
1 R1 임준욱 Anticoagulant and Antiplatelet Therapy Use in 426 Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention and Stent Implantation.
Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Efficacy and Safety of Dual Antiplatelet Therapy.
1 Analysis of Survival Data with Demographic Applications (Spring term 2006) Lecture 3: Non-Parametric Comparison of two or more Survival Curves.
Primer on Adjusted Indirect Comparison Meta-Analyses
Second Generation DES Associated with Less Late and Very Late Stent Thrombosis Compared to First Generation DES Donald E. Cutlip, MD Beth Israel Deaconess.
Statistics 103 Monday, July 10, 2017.
Giuseppe Biondi Zoccai
AN INTERNATIONAL COLLABORATIVE META-ANALYSIS ON 1,274 PATIENTS UNDERGOING PERCUTANEOUS DRUG-ELUTING STENTING FOR UNPROTECTED LEFT MAIN CORONARY ARTERY.
SURGERY EARLY AFTER DES IMPLANTATION
Benefits of complete coronary revascularization – Counterpoint: what are you talking about? Giuseppe Biondi Zoccai, MD University of Modena and Reggio.
Single Versus Multiple Vessel Stenting In Patients With St-Elevation Myocardial Infarction: Results From A 30,886-Patient Meta-Analysis Giuseppe Biondi.
Comparison of radial versus femoral access in patients undergoing invasive management for acute coronary syndromes: evidence from a systematic review and.
Is Prasugrel Superior To Ticagrelor For The Treatment Of Patients With Acute Coronary Syndromes? Evidence From A 32,893-Patient Adjusted Indirect Comparison.
Presentation transcript:

Primer on Statistics for Interventional Cardiologists Giuseppe Sangiorgi, MD Pierfrancesco Agostoni, MD Giuseppe Biondi-Zoccai, MD

What you will learn Introduction Basics Descriptive statistics Probability distributions Inferential statistics Finding differences in mean between two groups Finding differences in mean between more than 2 groups Linear regression and correlation for bivariate analysis Analysis of categorical data (contingency tables) Analysis of time-to-event data (survival analysis) Advanced statistics at a glance Conclusions and take home messages

What you will learn Analysis of time-to-event data (survival analysis) –Kaplan-Meier estimate of the survival function –Comparing distributions of time until occurrence of an event with the log-rank and Tarone-Ware tests

How can I decide which of 2 stents is safer in terms of freedom from long-term stent thrombosis? In other words, how can I quantitate and compare the risk of a given dichotomous event taking into account variable lengths of follow-up? Survival analysis

Patients experiencing one or more events are called responders Patients who, at the end of the observational period or before such time, get out of the study without having experienced any event, are called censored Survival analysis

Patients experiencing one or more events are called responders Patients who, at the end of the observational period or before such time, get out of the study without having experienced any event, are called censored Survival analysis Survival analysis expoits all units of information, giving adequate weight to each case, depending on the corresponding duration of follow-up in case of event occurrence or censoring

There are 2 methods available for survival analysis: –Actuarial survival analysis (life tables): the probability of survival is computed at fixed time points (eg every 30 days) → uncommonly used in clinical research (but your car insurance is based on this!), unless you have very extensive datasets –Product limit survival analysis (Kaplan-Meier): the probability of survival is computed every time an event occurs → most commonly used in clinical research, given the small datasets Survival analysis

Actuarial analysis (life tables)

Product limit (Kaplan-Meier) analysis

Survival conditional probability at time t j is: where q j = d j /n j is the conditional probability of failure at time t j The cumulative survival probability at t is: Product limit (Kaplan-Meier) analysis

Any survival curve has a ladder trend, with many steps Each step occurs when an event occurs, and the height of the step depends on the number of events and of censored data at each specific time Impact of a few changes in events

Any survival curve has a ladder trend, with many steps Each step occurs when an event occurs, and the height of the step depends on the number of events and of censored data at each specific time Impact of a few changes in events

Any survival curve has a ladder trend, with many steps Each step occurs when an event occurs, and the height of the step depends on the number of events and of censored data at each specific time Impact of a few changes in events

Kaplan-Meier curve: hazard Vlaar et al, Lancet 2008

Kaplan-Meier curve: hazard Lee et al, EuroInterv 2007

Kaplan-Meier curve: hazard Lee et al, EuroInterv 2007

Agostoni et al, Am J Cardiol 2005 Kaplan-Meier curve: survival

Agostoni et al, Am J Cardiol 2005 Kaplan-Meier curve: survival

Kaplan-Meier curves and SE Lotan et al, for the E-Five Registry Investigators, TCT month MACE after ZES implantation for AMI Time after Initial Procedure (days) 15% 12% 9% 6% 3% 0% Cumulative Incidence AMI <72 hr 6 – 24 hr <6 hr MACE AMI <72hr hr <6hr

Kaplan-Meier curves and CI Time since PCI in years Cumulative Incidence of ARC definite/probable ST % (17) — CYPHER Stent 2.1% (26) —TAXUS Stent Cypher & Taxus Pooled Analyses 1 1 Mauri et al, N Engl J Med % [95% CI] CYPHER & TAXUS (n=8,146) Bern-Rotterdam 2 2 Wenaweser et al, J Am Coll Cardiol 2008

What you will learn Analysis of time-to-event data (survival analysis) –Kaplan-Meier estimate of the survival function –Comparing distributions of time until occurrence of an event with the log-rank and Tarone-Ware tests

Comparison between survival curves is usually performed with the non-parametric Mantel-Haenzel- Cox test (aka, log-rank test) or its derivates: Gehan- Breslow and Tarone-Ware tests It may also be possible to stratify/adjust for other relevant factors which may be heterogeneously distributed across groups We thus create subgroups (strata) of cases with similar prevalence of such relevant factors Analysis maintains its alpha as the population is not truly dividided in subgroups, but rather analyzed as a whole Hypothesis testing for survival

The log-rank test is the most commonly used test The log-rank, Gehan-Breslow, and Tarone-Ware tests are quite similar, but differ in the weight they assign each survival value The Gehan-Breslow test weighs more earlier failures, while the log-rank test weighs equally all failures. The Tarone-Ware test falls in between Our suggestion is to use both log-rank and Tarone-Ware tests, hoping they agree on direction and magnitude of statistical significance Did you know…that If there is no censoring, the Mann- Whitney U rank sum test can be used? Which test should you use?

Kaplan-Meier and log-rank Marroquin et al, New Engl J Med 2008

Survival analysis with SPSS

Thank you for your attention For any correspondence: For further slides on these topics feel free to visit the metcardio.org website: